Clinical Scorecard: Efficacy of the 0.18 mg fluocinolone acetonide intravitreal implant in treating macular edema linked to non-infectious uveitis: Insights from a real-world analysis

At a Glance

Key Highlights

• 0.18 mg fluocinolone acetonide intravitreal implant (FAi) provides sustained corticosteroid release (0.2 µg/day) for up to 36 months
• Real-world study in Chinese NIU-ME patients showed improvements in visual acuity and macular thickness over 12 months
• FAi reduces uveitis recurrence rates and need for adjunctive therapy with an acceptable safety profile

Guideline-Based Recommendations

Diagnosis

• Confirm NIU-ME diagnosis via clinical signs, medical history, laboratory tests, ophthalmoscopy, fundus fluorescein angiography (FFA), and optical coherence tomography (OCT)
• Exclude infectious uveitis and other ocular pathologies (e.g., epiretinal membrane, vitreomacular traction) prior to treatment

Management

• Consider single intravitreal injection of 0.18 mg fluocinolone acetonide implant for chronic NIU-ME refractory to systemic corticosteroids and immunomodulatory agents
• Monitor and manage intraocular pressure and ocular adverse events during follow-up
• Use adjunctive anti-inflammatory therapy as needed based on recurrence assessment

Monitoring & Follow-up

• Regular assessment of best-corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) at baseline and scheduled intervals (1, 3, 6, and 12 months post-implant)
• Monitor for signs of uveitis recurrence including increased intraocular inflammation, worsening visual acuity, and macular edema
• Evaluate for ocular adverse events and systemic complications throughout follow-up

Risks

• Potential for increased intraocular pressure requiring management
• Possible ocular adverse events related to intravitreal corticosteroid implants
• Systemic side effects minimized compared to systemic corticosteroids but vigilance required

Patient & Prescribing Data

39 patients (50 eyes) with chronic, refractory NIU-ME; mean age 54.6 years; majority pseudophakic; prior systemic and local corticosteroid/immunosuppressive treatments

Single 0.18 mg FAi intravitreal implant demonstrated sustained efficacy over 12 months with improvements in BCVA and reduction in macular edema; well tolerated with manageable safety profile

Clinical Best Practices

• Ensure thorough baseline ophthalmic evaluation including BCVA, IOP, FFA, and OCT before implant
• Obtain informed consent detailing benefits and potential risks of FAi treatment
• Schedule regular follow-up visits to monitor efficacy and safety parameters
• Individualize recurrence assessment to guide adjunctive therapy decisions
• Consider FAi as a targeted therapy to reduce systemic corticosteroid exposure in chronic NIU-ME

References

• FDA Approval of Fluocinolone Acetonide Intravitreal Implant
• National Medical Products Administration (NMPA) Approval in China